Allay Therapeutics Completes Oversubscribed $60M Financing Led by Arboretum Ventures

Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced the completion of its oversubscribed $60M Series C financing, led by Arboretum Ventures.